Presymptomatic genetic testing for neurodegenerative diseases can help patients make effective treatment decisions, but the medical profession needs to ensure that the increasing use of the tests is done responsibly.
Three reports considered by the Council on Ethical and Judicial Affairs are described, along with the process for revising the AMA's Code of Medical Ethics and trivia about contraceptive use.